

## JNJ-46778212

Cat. No.: HY-19559 CAS No.: 1363281-27-9 Molecular Formula:  $C_{20}H_{17}FN_2O_3$ 

Molecular Weight: 352.36 Target: mGluR

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C

> 4°C 2 years

3 years

In solvent -80°C 2 years

> -20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (283.80 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8380 mL	14.1900 mL	28.3801 mL
	5 mM	0.5676 mL	2.8380 mL	5.6760 mL
	10 mM	0.2838 mL	1.4190 mL	2.8380 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description	JNJ-46778212 (VU 0409551) is an mGlu5 positive allosteric modulator with an EC <sub>50</sub> of 260 nM.
IC <sub>50</sub> & Target	mGlu5 Receptor 260 nM (EC50)
In Vivo	In oral brain/plasma studies, JNJ-46778212 displays excellent CNS penetration $^{[1]}$ . JNJ-46778212 enhances NMDAR function and rescues long-term potentiation in hippocampal slices obtained from SR $^{-/-}$ mice. The administration of JNJ-46778212 to

 $\mathsf{SR}^{-/-}\ \mathsf{mice}\ \mathsf{reverses}\ \mathsf{their}\ \mathsf{deficits}\ \mathsf{in}\ \mathsf{several}\ \mathsf{neuroplasticity}\ \mathsf{signaling}\ \mathsf{pathways}\ \mathsf{and}\ \mathsf{improves}\ \mathsf{their}\ \mathsf{contextual}\ \mathsf{fear}\ \mathsf{memory}^{[2]}$ 

.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **PROTOCOL**

Animal
Administration [1]

 $Mice^{[1]}$ 

SR<sup>-/-</sup> mice receive once daily, intraperitoneal (i.p.) injections of vehicle (20% hydroxypropyl  $\beta$ -cyclodextran) or VU0409551 for 5 days at a volume of 10 mL/kg. For the in vivo pharmacokinetic and dose-finding experiments, WT mice (n=5-6/dose) receive vehicle or VU0409551 (10 and 30 mg/kg). For the SR<sup>-/-</sup> mice reversal studies, WT mice receive vehicle and SR<sup>-/-</sup> mice receive either vehicle or VU0409551 (30 mg/kg). All mice are killed 2 h after the last injection on day  $5^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Conde-Ceide S, et al. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Med Chem Lett. 2015 May 20;6(6):716-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA